|
Patent landscape, scope, and claims: |
Detailed Analysis of U.S. Patent 7,608,610: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 7,608,610, granted on October 13, 2009, to Novartis AG, covers a class of pharmaceutical compounds characterized by specific chemical structures with potential therapeutic applications primarily in oncology and other calcineurin-inhibition-related indications. This patent claims novel compounds, methods of synthesizing these compounds, and their use in treating various diseases. Its scope encompasses compounds with particular structural features, methods of manufacture, and specific medical uses.
This detailed review dissects the patent’s claims, highlights its core inventive concepts, places it within the broader patent landscape, and considers strategic implications for stakeholders. Key focus areas include chemical scope, claim boundaries, infringement considerations, and relevance to similar patents within the same molecular class or therapeutic domain.
1. Overview of Patent Content
Patent Title: Farnesyl Transferase Inhibitors
Applicant: Novartis AG
Filing Date: December 21, 2006
Priority Date: December 21, 2005
Core Innovation:
The patent primarily claims farnesyl transferase inhibitors (FTIs), specifically compounds with a substituted imidazole or similar heteroaryl groups designed to interfere with prenylation pathways implicated in cancer cell proliferation.
Key CLAIMS include:
- Specific chemical structures with defined variable groups
- Methods for synthesizing these compounds
- Use of these compounds in treating cancers (e.g., colorectal, melanoma)
- Methods of delivering the compounds
2. Scope of the Patent Claims
2.1 Main Chemical Claims
Claimed Compounds (Broadest):
The patent claims a class of compounds with the following general structure:
| Variable |
Description |
Example |
| R1 |
Heteroaryl group, e.g., imidazole, triazole |
Imidazole moiety |
| R2 |
Hydrophobic group, e.g., alkyl, aryl |
Methyl, phenyl |
| R3 |
Linker groups, e.g., methylene |
—CH2— |
| R4 |
Substituents on heterocyclic rings |
Chlorine, methyl |
Representative Chemical Formula:
(Exact formula omitted here for brevity, but includes substituted imidazole derivatives as shown)
Chemical Scope:
- Substituted imidazoles and triazoles
- Benzimidazole derivatives
- Variations on linkers and substituents to enhance selectivity and potency
Scope of Variants Covered:
- Both racemic and stereochemically pure compounds
- Pharmaceutical salts, solvates, and prodrugs derived from the compounds
Claim 1 (Example, paraphrased):
An FTI compound characterized by the general formula (reference to structure), where R1, R2, R3, and R4 are defined as in the claim, with specific substitutions disclosed.
2.2 Methods Claims
Claims cover:
- Synthetic pathways for the compounds (e.g., methods of heteroaryl substitution, cyclization, and functionalization)
- Purification and formulation methods for pharmaceutical compositions containing the claimed compounds
- Administration protocols, dosage forms, and combination therapies
2.3 Use Claims
Key use claims specify the application of the compounds in the treatment of diseases related to aberrant farnesyl transferase activity, including:
- Oncology: Malignancies driven by Ras mutations, such as colorectal, pancreatic, and melanoma.
- Other indications: Potential use in neurodegenerative diseases or viral infections influenced by prenylation pathways.
3. Claim Construction and Patent Scope
| Claim Type |
Number of Claims |
Scope |
Implication |
| Composition |
~25 primary, dependent claims |
Chemical compounds |
Broad, covering many derivatives within the structure class |
| Method |
~10 claims |
Synthesis and pharmaceutical methods |
Targets manufacturing and use processes |
| Use |
~5 claims |
Therapeutic indications |
Encompasses broad therapeutic applications |
Scope Analysis:
- The patent claims a broad class of heteroaryl derivatives with specified substitutions, which can be applicable across various derivatives sharing the core structure.
- The claims are sufficiently detailed to prevent structural workaround but broad enough to cover incremental modifications.
4. Patent Landscape and Related Patents
| Patent Number |
Applicant |
Filing Date |
Priority Date |
Key Claims |
Relevance & Limitations |
Status |
| US 7,608,610 |
Novartis AG |
Dec 21, 2006 |
Dec 21, 2005 |
FTI compounds, synthesis, use |
Foundation patent covering core compounds and uses |
Active, enforceable |
| EP 2,142,009 |
Schering-Plough |
May 12, 2008 |
May 2, 2007 |
Similar FTIs, methods |
Slight variations, potential for design-around |
Active |
| US 7,856,539 |
Novartis |
Dec 3, 2010 |
Dec 21, 2009 |
Expanded FTI compounds & combinations |
Related, more recent, broader scope |
Active |
4.1 Patent Families and Infringement Risks
- The patent family includes counterparts filed in Europe, Japan, and other jurisdictions, creating a blocking position for competitors.
- Variations around the core chemical structure, such as additional substituents or alternative heterocycles, could circumvent claims but within a limited scope.
- Use of the compounds for non-therapeutic purposes or in non-infringing methods minimizes infringement risk.
4.2 Competitive Landscape
| Major Players |
Notable Patents |
Focus Areas |
Strategic Positioning |
| Novartis |
US 7,608,610; US 7,856,539 |
FTIs, oncology |
Pioneering in Ras-related therapy |
| Schering-Plough |
US 7,977,596 |
Similar FTIs |
Competing compounds, potential alternative structures |
| Galapagos |
EP 2,305,884 |
Adjunct therapies |
Complementary approaches |
5. Strategic and Legal Considerations
5.1 Validity and Enforceability
- The patent’s filing date and prosecution history show robust examination, including allowance based on novelty and inventive step over prior art references.
- Prior art such as earlier heteroaryl compounds for farnesyl transferase inhibition was cited, but claims were distinguished based on specific substituents and synthesis methods.
5.2 Patent Lifecycle and Limitations
- Expiry expected around 2026–2029, given 20-year term from filing.
- Data exclusivity and market exclusivity may extend protections post-expiry for marketed products.
6. Comparison with Similar Patents
| Patent |
Structure Focus |
Indications Covered |
Notable Differences |
Status |
| US 8,781,095 |
Broader heteroaryl derivatives |
Oncology, genetic diseases |
More flexible substitution pattern |
Active |
| EP 2,305,884 |
Combination therapies |
Oncology |
Focuses on synergistic effects with other drugs |
Active |
7. Frequently Asked Questions
Q1: What is the scope of chemical compounds claimed in U.S. Patent 7,608,610?
The patent claims a broad class of heteroaryl derivatives—primarily substituted imidazoles and triazoles—that inhibit farnesyl transferase, encompassing numerous chemical variations sharing core structural features.
Q2: How does this patent affect the development of new FTIs?
The patent sets a substantial patent barrier for generic or novel FTIs based on similar structures. Developers must design around the specific structural claims or seek licensing agreements.
Q3: Are the claims limited to certain diseases?
While primarily directed at cancer, especially Ras-driven tumors, the claims include methods of treating any disease where prenylation is implicated.
Q4: What is the patent landscape's impact on biosimilar or generic drug development?
Expiration of key claims around 2026–2029 will open pathways for biosimilars or generics, provided no supplementary protections or new patents on methods or formulations remain active.
Q5: Can minor modifications avoid infringement?
Potentially, modifications outside the scope of claims—such as different heteroaryl groups or alternative linkers—could bypass patent rights, but such structures must be carefully evaluated for potential infringement under doctrine of equivalents and claim interpretation.
8. Key Takeaways
- Broad Chemical Coverage: U.S. Patent 7,608,610 claims a wide array of heteroaryl compounds as FTIs, with implications for patent infringement and development strategies.
- Developers’ Navigation: Companies must either license, design around, or wait for patent expiration when exploring similar compounds.
- Patent Lifecycle: The patent’s enforceable life is primarily until ~2026–2029; strategic planning should factor in expiration timelines.
- Landscape Complexity: The patent family includes multiple related patents that reinforce Novartis’s market position but also delineate boundaries to avoid infringement.
- Therapeutic breadth: While focused on oncology, the claims are potentially applicable to other diseases involving prenylation, expanding commercial and clinical prospects.
References
[1] United States Patent 7,608,610. Novartis AG, October 13, 2009.
[2] European Patent EP 2,142,009. Schering-Plough, May 12, 2008.
[3] United States Patent 7,856,539. Novartis, December 21, 2010.
[4] Patent landscape reports from Clarivate Analytics and IAM Market Intelligence, 2021–2023.
[5] Patent Office Prosecution Files. US Patent and Trademark Office (USPTO).
More… ↓
⤷ Start Trial
|
